Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 28 July 2021
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Risdiplam for treating spinal muscular atrophy (TA755)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 15 December 2023Published: 16 December 2021
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 July 2022
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 October 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 July 2021
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2010
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 22 January 2025
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 February 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years TS ID 11887Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC